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Abstract
Background: To evaluate the ocular pulse amplitude (OPA) in patients with chronic non-arteritic anterior ischaemic
optic neuropathy (NAION).
Methods: This cross-sectional study comprised a study group of 30 eyes from 30 patients with NAION and a control
group of 31 eyes from 31 age and gender-matched healthy subjects. Bilateral OPA was measured with dynamic
contour tonometry (DCT) and was compared between the study and control groups.
Results: No statistically significant difference was found between the study and control groups in terms of hypertension,
diabetes mellitus, ischaemic heart disease and hyperlipidemia. The mean intraocular pressure (IOP) measured with
Goldmann Applanation Tonometry and DCT in the study and control groups was not statistically different (p1 = 0.094,
p2 = 0.240). The mean OPA in the study group and the control group were 2.01 ± 0.69 mmHg and 1.97 ± 0.68 mmHg
(p = 0.839).
Conclusion: No significant difference was determined in the OPA levels of eyes with NAION at the chronic stage and
eyes in the control group.
Keywords: Dynamic contour tonometry, Intraocular pressure, Ocular blood flow, Optic nerve, Short posterior
ciliary arteries
Background
Anterior ischaemic optic neuropathy (AION) is a conse-
quence of ischaemic injury to the anterior section of the
optic nerve, which is an area of circulation fed by the
posterior ciliary arteries. There are 2 types of AION:
arteritic AION (AAION), which develops secondary to
vasculitis (primarily giant cell arteritis), and non-arteritic
AION (NAION), which develops secondary to non-
inflammatory small vessel disease [1–3]. NAION consti-
tutes 95% of all AION and in those aged >50 years, is
the most frequent cause of acute optic neuropathy. The
annual incidence among those aged >68 years has been
estimated to be 82 per 100,000 and 0.54 per 100,000 for
all age groups [4, 5].
It is thought that NAION results from inadequate cir-
culation within the optic nerve head, although there has
not yet been any conclusive proof of the specific location
of the vasculopathy and the pathogenetic mechanism
[6]. Normally, blood flow remains stable by perfusion
pressure, intraocular pressure (IOP) and metabolic condi-
tions (including tissue oxygen and carbondioxide levels).
Arteriosclerosis, vasospasm, or medications such as beta-
blockers or other antihypertensive drugs can disrupt the
autoregulatory mechanism. In patients with NAION,
there is reduced blood flow in the short posterior ciliary
arteries (SPCAs) [7], although there has been no histo-
pathological evidence of thrombosis of the SPCAs in the
very few cases that have been studied [8, 9]. Therefore, it
is believed that the condition is caused by generalized
hypoperfusion in some cases and by occlusion of disc or
laminar capillaries in others.
Extended pulsatile oscillations of IOP during the cardiac
cycle are represented by ocular pulse amplitude (OPA).
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In cases of giant cell arteritis, OPA has been demon-
strated to be significantly reduced, and may therefore
be helpful in the prediction of NAION risk [10–13].
The aim of the present study was to evaluate OPA in
patients with NAION at the chronic stage.
Methods
A review was made of patients diagnosed with NAION,
who were admitted to the Ophthalmology Clinic at
Bozyaka Training and Research Hospital, Izmir, Turkey
between 2011 and 2015. The study group included a
total of 30 eyes of 30 patients who attended the clinic
for a routine check-up between June 2014 and October
2015 and a control group included a total of 31 patients
who attended the clinic for a refraction examination.
The medical records of all patients were reviewed and a
comparison was made of the study group and the control
group. The study was conducted in accordance with the
tenets of the Declaration of Helsinki, with approval from
the Local Ethics Committee of this hospital. Informed
consent for participation in this study was obtained from
each participant.
The criteria required for diagnosis of NAION were as
follows: (1) a history of sudden visual loss and an ab-
sence of other ocular, orbital, systemic, or neurological
diseases that may influence or explain the patient’s visual
symptoms; (2) presence of optic disc edema at the time
the patient came to medical attention shortly after the
onset of acute symptoms; (3) spontaneous resolution of
optic disc edema was observed; and (4) the eye had optic
disc-related visual field defects.
Patients were excluded if they had media opacities
that would preclude fundus examination or visual field
evaluation, glaucoma, coexistence of ophthalmic or
neurological disease, or any other retinal pathology, or
if they had undergone previous eye surgery other than
uneventful cataract surgery. Patients with diabetes mellitus
were included, but those who had vitreous hemorrhages,
traction detachment, or other complications influencing
visual acuity or visual fields were excluded. Eyes with
unreliable visual fields were excluded. In addition, patients
who were in the acute stage of NAION were excluded
from the study, in order to minimise the effects of optic
disc swelling.
The control group consisted of subjects with no history
of chronic ocular or systemic disease or of ocular surgery
other than uneventful cataract surgery. The inclusion cri-
teria for this group were that they had a normal visual field
test, IOP of less than 21 mmHg, a normal, symmetric optic
disc head between left and right eyes, an open anterior
chamber angle, no history of chronic, ocular or systemic
corticosteroid use, spherical refraction of < ±5.00 dioptres
and astigmatism of < ±3.00 dioptres.
A detailed medical history was taken from each partici-
pant including all previous or current systemic diseases,
with particular focus on arterial hypertension, diabetes
mellitus, ischaemic heart disease and hyperlipidemia.
Blood pressure measurements were taken using a brachial
sphygmomanometer (DS66, Welch Allyn, Skaneateles,
NY, USA) and a Littmann Classic II stethoscope (3 M, St
Paul, MN, USA) on the upper right-side arm after a rest
period of at least 5 minutes. Patients were told to abstain
from caffeine, exercise, and smoking for at least 30 minutes
before the examination. The measurements were repeated
after a 5-minute interval and the average of the two values
was recorded. The height (in centimeters) and weight
(kilograms) of the patients were measured using a
standard scale, and in light clothing and bare feet, and
noted. Body Mass Index (BMI) was calculated using the
formula weight (kg)/height squared (m2).
A comprehensive ophthalmic evaluation was performed
at that time, which included (1) recording of the best-
corrected visual acuity (BCVA) using a Snellen chart, (2)
the visual field measurement using a Humphrey Auto-
mated Field Analyzer (Carl Zeiss Meditec Inc, Dublin,
CA, USA) program 30–2 and the standard Swedish inter-
active threshold algorithm (SITA) strategy, (3) slit-lamp
examination of the anterior segment, lens, and vitreous,
(4) IOP with Goldmann applanation tonometry (GAT)
and dynamic contour tonometry (DCT, PASCAL, Swiss
Microtechnology AG, a Ziemer Ophthalmic Systems
Group Company), (5) OPA with DCT, (6) The central cor-
neal thickness (CCT) was measured three times using
ultrasonic pachymetry with a Pacscan 300P USP device
(Sonomed Inc., Lake Success, NY, USA) (6), direct and
indirect ophthalmoscopy and (7) color fundus photog-
raphy. OPA measurements were taken using a slit
lamp-mounted DCT device at the same time of day
(09:00–10:00) in all cases, thus avoiding diurnal fluctua-
tions. All the measurement procedures were applied by
the same two experienced ophthalmologists (DA and
OK) according to the manufacturer’s recommendations.
Only Quality index (‘Q’) readings of 1 or 2 (range: 1–5,
with higher values indicating lower quality) were in-
cluded in the analysis. The ‘OPA’ value of each eye was
calculated as the mean of three consecutive readings. Both
eyes were examined in the study and control groups but
only the values of the right eyes of the control group were
used for analyses.
Statistics were analyzed using SPSS software version
15.0 (SPSS, Inc, Chicago, Illinois, USA). The data were
given as mean values ± SDs. The Gaussian distribution
of the parameters was tested using the Kolmogorov–
Smirnov test. Continuous variables were compared be-
tween the groups using the Student t-test and categorical
variables were compared using the χ2 test. The Pearson
Chi-square test with Yates continuity correction or the
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Fisher exact test, as appropriate, were used for frequency
distribution comparisons. All tests were two tailed, and
significance was set at 0.05.
Results
The study group included 30 eyes of 30 patients (14
males, 16 females) with NAION. The mean age was
54.67 ± 10.54 years, the mean refractive error was +0.38
± 1.43 (range, −3.75 to +4.00) diopters and the mean
follow-up was 2.01 years (range, 0.30 – 10 years) in the
study group. Two patients had bilateral NAION and
their right eyes were evaluated. The control group in-
cluded 31 eyes of 31 patients (10 males, 21 females) with
no abnormality of the fundus. The mean age in the con-
trol group was 53.39 ± 6.67 years, and the mean refractive
error was +0.47 ± 1.12 (range, −3.50 to +3.25) diopters.
No statisically significant difference was determined be-
tween the study group and the control group in respect of
refractive error, age and gender (p1 = 0.788, p2 = 0.575 and
p3 = 0.249, respectively). Descriptive statistics for the
demographic, ocular and systemic characteristics of the
study and control groups are shown in Table 1. Compared
to the control group, patients with NAION had a greater
prevalence of hypertension (40.0 vs. 29.0%; p = 0.367), dia-
betes mellitus (30.0 vs. 22.6%; p = 0.510), ischaemic heart
disease (13.3 vs 9.7%; p = 0.707) and hyperlipidemia (26.7
vs. 12.9%; p = 0.176) but the difference was not statistically
significant. The mean BMI values in the study and control
groups were 29.08 ± 5.23 and 27.77 ± 4.67, respectively
(p = 0.304). The mean systolic blood pressure (SBP) in
the study group and the control group was 122.83 ±
13.11 mmHg and 118.71 ± 15.97 mmHg, respectively
(p = 0.276). The mean diastolic blood pressure (DBP)
was also not statistically different (77.70 ± 7.66 mmHg
in the study group vs. 75.00 ± 11.25 mmHg in the con-
trol group; p = 0.279).
The mean BCVA measured with a Snellen chart was
0.35 ± 0.37 in the study group and 0.96 ± 0.09 in the con-
trol group (p < 0.001). In the study group, the time since
the NAION attack ranged from 4 months to 10 years
(mean, 2.01 years). The mean IOP with GAT in the
study and control groups was 13.73 ± 2.30 mmHg and
14.84 ± 2.74 mmHg, respectively (p = 0.094). The IOP with
DCT was 13.58 ± 1.81 mmHg and 14.20 ± 2.22 mmHg, re-
spectively for the study and control groups (p = 0.240).
The mean OPA in the study group and the control group
was 2.01 ± 0.69 mmHg and 1.97 ± 0.68 mmHg (p = 0.839)
(Fig. 1). The OPA measurements were compared between
the affected eyes and the contralateral unaffected eyes
within the group of patients with unilateral NAION and
without histories of previous NAION in the contralateral
eye. The mean OPA values in the affected eyes of the uni-
lateral NAION (28 eyes) were significantly lower than the
unaffected contralateral eyes (1.95 ± 0.67 mmHg and 2.15
± 0.61 mmHg, respectively, p = 0.035, Wilcoxon Signed
Ranks Test). However, the difference between the mean
OPA of the affected eyes of the unilateral NAION and
the mean OPA of the control group was not statistically
significant (p = 0.857).
Discussion
In this study, the OPA values in patients with NAION
were investigated and it was also examined whether
OPA was an indicator for identifying eyes with NAION
from healthy eyes. OPA with DCT is a non-invasive,
safe, fast and readily available procedure, therefore, in
most cases, it can be easily integrated into the diagnostic
work-up [14, 15]. Typically, reduced OPA values are
measured in carotid artery stenosis or encircling buckles
for retinal detachment [16, 17]. OPA is thought to be a
potential alternative parameter for ocular blood flow
measurement and although there have been studies of
glaucoma association [18], there has not been much re-
search related to NAION. In a study by Weizer et al.,
OPA was found to be correlated with the severity of
glaucoma, with high OPA seeming to indicate less severe
glaucoma [19]. Schwenn et al. demonstrated that eyes
with normal tension glaucoma were more likely to have
low OPA than those with primary open angle glaucoma,
ocular hypertension, or normal eyes [20]. Kynigopoulos
et al. reported that low OPA was related to functional and
structural damage in primary open angle glaucoma [21].
Table 1 Demographic, ocular and systemic characteristics of the
tested subjects
Study group Control group p value
(n = 30 eyes) (n = 31 eyes)
Mean age (year ± SD) 54.67 ± 10.54 53.39 ± 6.67 0.575
Gender, no. of females (%) 16 (53.3%) 21 (67.7%) 0.249
BMI, mean (SD), kg/m2 29.08 ± 5.23 27.77 ± 4.67 0.304
Hypertension n,(%) 12 (40.0%) 9 (29.0%) 0.367
SBP, mmHg 122,83 ± 13.11 118.71 ± 15.97 0.276
DBP, mmHg 77.70 ± 7.66 75.00 ± 11.25 0.279
Ischaemic heart disease n, (%) 4 (13.3%) 3 (9.7%) 0.707
DM n, (%) 9 (30.0%) 7 (22.6%) 0.510
Hyperlipidemia n, (%) 8 (26.7%) 4 (12.9%) 0.176
BCVA 0.35 ± 0.37 0.96 ± 0.09 <0.001
Spheric equivalant, mean 0.38 ± 1.43 0.47 ± 1.12 0.788
Mean GAT, mmHg ± SD 13.73 ± 2.30 14.84 ± 2.74 0.094
Mean DCT, mmHg ± SD 13.58 ± 1.81 14.20 ± 2.22 0.240
Mean OPA, mmHg ± SD 2.01 ± 0.69 1.97 ± 0.68 0.839
CCT, μm 536.47 ± 35.04 546.61 ± 30.03 0.229
Abbreviations BCVA best-corrected visual acuity, BMI body-mass index, CCT central
corneal thickness, DBP diastolic blood pressure, DCT, dynamic contour tonometer,
DM diabetes mellitus, GAT Goldmann applanation tonometry, OPA ocular pulse
amplitude, SBP systolic blood pressure.
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In contrast, the results of a study by Figueiredo et al.,
showed significantly lower mean OPA in the control
group than in the patients with glaucoma or ocular hyper-
tension [22].
Another study compared OPA in patients with giant cell
arteritis and those with NAION or non-arteritic central
retinal artery occlusion [13] and the mean pulse amplitude
of patients with AAION was determined to be only 37%
of the mean value of the non-arteritic group. In a different
study, the mean OPA with pneumotonometer was seen to
be reduced in patients with temporal arteritis but not in
cases where AION was not caused by temporal arteritis
[12]. However, these studies are old and there is no
current study with new techniques, such as DCT, for com-
parision of NAION and healthy eyes.
Knecht et al. evaluated the OPA values of the eyes of
31 patients with suspected giant cell arteritis and con-
firmed the association of reduced OPA levels in giant
cell arteritis. The findings were also supportive of an
algorithm based on OPA, erythrocyte sedimentation rate
and thrombocyte count, which has the potential to pro-
vide valuable assistance in the clinical management of
giant cell arteririts [23]. As OPA has been shown to be
markedly reduced in giant cell arteririts, the hypothesis
of the current study was that it may be helpful in pre-
dicting the likelihood of NAION [10–13].
In this study, OPA was compared between patients
with NAION and a healthy control group. There was no
difference between the two groups in terms of gender,
age, spherical equivalent refraction and systemic charac-
teristics. The OPA values in NAION were not found to
be any different from those of the eyes in the control
group. However, the mean OPA values in the affected
eyes of the patients with unilateral NAION were statisti-
cally lower than those of the unaffected contralateral
eyes. The increase in OPA values of the unaffected
contralateral eyes might have developed psychologically
to protect the unaffected eye, but the mechanism is un-
clear. In a previous study, eyes affected by NAION and
unaffected contralateral eyes showed significantly thinner
macular choroids than eyes of a control group after
adjusting ocular and systemic parameters [24]. It was
claimed that a thin macular choroid may thus potentially
be a risk factor for the development of NAION and it may
be an indicator for changed blood circulation at the pos-
terior pole [24]. Blood supply to both the choroid and the
anterior section of the optic nerve head is provided by the
SPCAs [25]. Therefore, a chronic, but balanced, vascular
Fig. 1 Boxplot showing the mean OPA in the study group and the control group
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insufficiency in these arteries could be considered to de-
compensate with an acute event in the optic nerve head
region such as an overnight capillary occlusion together
with a nocturnal decrease in arterial blood pressure [24].
However, Hayreh reported that the choroidal vascular bed
(except for the small peripapillary choroid), has no role in
the blood supply of the optic nerve head [26]. The total
blood flow in the choroid and changes in it do not give a
true picture of the blood flow in the optic nerve head.
Total ocular blood flow has pulsatile and nonpulsatile
components. In a study by Arnold et al. choroidal fluores-
cein flow was normal in eyes with NAION, indicating no
restriction in the choroidal blood supply [27]. However, in
experimental studies, optic nerve capillaries have been
shown to be largely derived from feeder branches derived
from the choroidal vasculature surrounding the optic
nerve [28]. Hayreh stated that NAION is a hypotensive
disorder, arising from transient noctural non-perfusion or
hypoperfusion of the blood vessels in the optic nerve head,
and is not caused by occlusion of the SPCAs as has been
frequently previously claimed [29]. The lack of consistent
choroidal filling delay demonstrated in fluorescein angiog-
raphy studies of NAION has suggested that the impaired
perfusion originates in the paraoptic tributaries of the
SPCAs, which are distal to the split from the choroidal
branches [30]. This, therefore, could explain the lack of
any change in the OPA results in the current study.
There are some limitations of the current study.
Pourjavan et al. found that in normal healthy eyes, the
OPA remained stable during normal outpatient office
hours and was not correlated with the blood pressure
of patients [31]. However, in eyes with NAION or at risk
of NAION, this strategy may not be valid. Nocturnal
hypotension could have an effect on OPA values. The
other limitation was the low number of patients. Although
efforts were made to recruit as many samples as possible,
it is accepted that the small sample size of this study may
cause a weakness in the statistical results.
Conclusions
OPA levels in the eyes with NAION were not found to
be significantly different from those of the control eyes.
This result could be clinically important in the differen-
tiation between NAION and AAION at the chronic
stage, in accordance with previous studies that have
shown reduced OPA levels in AAION. However, pro-
spective studies with larger sample sizes are needed to
confirm these findings.
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